Amgen’s first quarter results reflected robust demand across its portfolio, with product volumes and sales increasing in both ...

Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an ...

While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, ...

Amgen shares fell sharply on Monday afternoon after the company released results from a weight-loss trial that showed that ...

Shares of Amgen Inc. AMGN rallied 1.03% to $280.35 Wednesday, on what proved to be an all-around mixed trading session for ...

A new drug from California-based pharma company Amgen, which has concluded a phase II trial, shows promise as a powerful ...

Amgen (AMGN) closed the most recent trading day at $280.35, moving +1.03% from the previous trading session. On the other hand, the Dow registered a loss of 0.25%, and the technology-centric Nasdaq ...

Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...

Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether ...

Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Lake Forest Hospital, joins John Williams to talk about ...

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...